• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pluri Inc. filed SEC Form 8-K: Other Events

    6/1/26 4:06:43 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    false 0001158780 0001158780 2026-05-28 2026-05-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC  20549

     

    FORM 8-K

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): June 1, 2026 (May 28, 2026)

     

    PLURI INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada   001-31392   98-0351734
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    MATAM Advanced Technology Park     
    Building No. 5    
    Haifa, Israel   3508409
    (Address of Principal Executive Offices)   (Zip Code)

     

    011 972 74 710 7171

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Shares, par value $0.00001 per share   PLUR   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    As previously disclosed, Pluri Inc. (the “Company”), together with its subsidiaries, Pluri Biotech Ltd., incorporated under the laws of Israel, and Pluristem GmbH, incorporated under the laws of Germany, entered into a finance agreement with the European Investment Bank (“EIB”) providing for up to €50 million in funding, of which only the first tranche of €20 million was disbursed in June 2021, and such amount bears interest at 4% per annum, and was scheduled to become repayable on June 1, 2026 (the “EIB Loan”). The Company also previously disclosed that on April 21, 2026, the Company received notice from the EIB that the EIB was reserving all of its rights under the finance agreement while discussions concerning potential alternatives, including a possible extension of the maturity date, remained ongoing.

     

    On May 28, 2026, the EIB confirmed to the Company that the parties remain engaged in constructive discussions in good faith with the objective of exploring a mutually agreed resolution regarding the EIB Loan. The EIB further advised that such discussions and negotiations are not expected to extend beyond July 3, 2026, and that during that period, and without prejudice to any of the EIB’s rights and remedies, no enforcement action is currently contemplated while discussions remain ongoing. The EIB reserved all rights, including the right to take action should the discussions not result in an outcome acceptable to the EIB. No assurance can be given that the parties will reach a mutually acceptable resolution or that the EIB will continue to refrain from exercising remedies available to it under the finance agreement.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements regarding discussions with the EIB, and the potential resolution of matters relating to the EIB Loan. Words such as “may”, “will”, “should”, “could”, “would”, “expect”, “intend”, “plan”, “believe”, “estimate”, “target”, “potential”, “continue”, “anticipate”, “seek”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

     

    Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Risks and uncertainties include, among others, the outcome and timing of the Company’s discussions with the EIB regarding the EIB Loan, whether those discussions result in a mutually agreed resolution, the Company’s liquidity position and need for additional financing, general market and economic conditions, the possibility that the EIB may exercise remedies under the finance agreement and other risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in other filings the Company makes with the U.S. Securities and Exchange Commission (the “SEC”). Forward-looking statements speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PLURI INC.
       
    Date: June 1, 2026 By: /s/ Liat Zalts
      Name:  Liat Zalts
      Title: Chief Financial Officer

     

    2

     

    Get the next $PLUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

    Two regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has completed the development and U.S. cosmetic product listings of two flag

    6/2/26 7:30:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

    HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further

    3/26/26 8:30:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

    Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships  HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra

    2/18/26 8:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    5/4/26 3:37:04 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    1/5/26 7:43:14 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein was granted 519 shares, increasing direct ownership by 5% to 10,769 units (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    12/8/25 4:07:47 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    SEC Filings

    View All

    Pluri Inc. filed SEC Form 8-K: Other Events

    8-K - Pluri Inc. (0001158780) (Filer)

    6/1/26 4:06:43 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Pluri Inc.

    10-Q - Pluri Inc. (0001158780) (Filer)

    5/14/26 4:01:42 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.

    SCHEDULE 13D/A - Pluri Inc. (0001158780) (Subject)

    5/1/26 7:57:53 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein was granted 10,250 shares, exercised 1,002,169 shares at a strike of $0.00 and bought $2,086,956 worth of shares (452,702 units at $4.61) (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    11/20/25 11:35:50 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    View All

    Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

    HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

    3/6/24 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

    HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

    7/13/23 2:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/13/24 4:34:49 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/1/24 4:02:29 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    9/15/23 4:00:03 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

    Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

    11/11/24 6:00:00 AM ET
    $BCLI
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care